Abstract:BACKGROUND: Oxidative stress, propelled by reactive oxygen species (ROS), serves as a significant catalyst for atherosclerosis (AS), a primary contributor to vascular diseases on a global scale. Antioxidant therapy via nanomedicine has emerged as a pivotal approach in AS treatment. Nonetheless, challenges such as inadequate targeting, subpar biocompatibility, and limited antioxidant effectiveness have restrained the widespread utilization of nanomedicines in AS treatment. This study aimed to synthesize a specialized peptide-modified liposome capable of encapsulating two antioxidant enzymes, intending to enhance targeted antioxidant therapy for AS.METHODS: The film dispersion method was employed for liposome preparation. Fluorescence quantification was conducted to assess the drug encapsulation rate. Characterization of liposome particle size was performed using dynamic light scattering (DLS) and transmission electron microscopy (TEM). Laser confocal microscopy and flow cytometry were utilized to analyze liposome cell uptake and target foam cells. Antioxidant analysis was conducted using 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA) staining, while pro-lipid efflux analysis utilized Oil Red O (ORO) staining. Safety evaluation was performed using Hematoxylin and Eosin (H&E) staining. The level of inflammatory factors was determined through enzyme-linked immunosorbent assay (ELISA). The degree of lipid oxidation at the cellular level was assessed using the malonaldehyde (MDA) assay. In vivo targeting analysis was conducted using small animal live imaging.RESULTS: Our in vitro and in vivo findings substantiated that the modification of Lyp-1 led to increased delivery of antioxidant enzymes into foam cells (p < 0.05), the primary pathological cells within AS plaques. Upon accumulation in foam cells, liposomes loaded with superoxide dismutase (SOD) and catalase (CAT) (LyP-lip@SOD/CAT) effectively mitigated excess ROS and shielded macrophages from ROS-induced damage (p < 0.01). Furthermore, the reduction in ROS levels notably hindered the endocytosis of oxidized low-density lipoprotein (Ox-LDL) by activated macrophages, subsequently alleviating lipid accumulation at atherosclerotic lesion sites, evident from both in vitro and in vivo ORO staining results (p < 0.01). LyP-lip@SOD/CAT significantly curbed the secretion of inflammatory factors at the plaque site (p < 0.001). Additionally, LyP-lip@SOD/CAT demonstrated commendable biological safety.CONCLUSIONS: In this study, we effectively synthesized LyP-lip@SOD/CAT and established its efficacy as a straightforward and promising nano-agent for antioxidant therapy targeting atherosclerosis.

Nanoparticle-Directed Antioxidant Therapy Can Ameliorate Disease Progression in a Novel, Diet-Inducible Model of Coronary Artery Disease

Abstract 128: Safety and Efficacy of Pro-efferocytic Nanoparticles to Treat Atherosclerosis in A Porcine Model

Inflammatory Endothelium-Targeted and Cathepsin Responsive Nanoparticles Are Effective Against Atherosclerosis

Abstract 451: PNS-R1 Attenuates the Development of Atherosclerosis in ApoE-Deficient Mouse Model

Theranostic nanoplatform to target macrophages enables the inhibition of atherosclerosis progression and fluorescence imaging of plaque in ApoE(−/−) mice

N-acetylcysteine attenuates atherosclerosis progression in aging LDL receptor deficient mice with preserved M2 macrophages and increased CD146

Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis

Living Macrophage-Delivered Tetrapod PdH Nanoenzyme for Targeted Atherosclerosis Management by ROS Scavenging, Hydrogen Anti-inflammation, and Autophagy Activation

Abstract P278: Coronary Microvascular Dysfunction Is Associated With Augumented Autophagy-lysosomal Signaling In Mice With Hypercholesterolemic Diet

Foam Cell Targeted Liposomes Co-Encapsulating Superoxide Dismutase and Catalase to Attenuate Atherosclerosis by Inhibiting Oxidative Stress

Abstract 028: Endothelial Nogo-B Controls Sphingolipid De Novo Biosynthesis to Impact Coronary Artery Atherosclerosis

Nintedanib ameliorates oxidized low-density lipoprotein -induced inflammation and cellular senescence in vascular endothelial cells

A severe atherosclerosis mouse model on the resistant NOD background

Targeted Delivery of Nanoparticles to Blood Vessels for the Treatment of Atherosclerosis

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Myriocin and D-PDMP Ameliorate Atherosclerosis in ApoE &Lt;sup>-/-</sup> Mice Via Reducing Lipid Uptake and Vascular Inflammation

949 OXYGENATED CAROTENOID LUTEIN SUPPLEMENTATION AGAINST EARLY ATHEROSCLEROSIS IN APOE-DEFICIENT MICE THROUGH ALLEVIATION THE DYSLIPIDEMIA AND ATTENUATION THE OXIDATIVE STRESS

Hyperlipidemia Induces Typical Atherosclerosis Development in Ldlr and Apoe Deficient Rats.

Scavenger Receptor Class B Type 1 Deletion Led to Coronary Atherosclerosis and Ischemic Heart Disease in Low-density Lipoprotein Receptor Knockout Mice on Modified Western-type Diet.

Abstract 139: Precision Nanomedicine Targeting Novel Endothelial Mechano-sensing Mechanisms To Treat Vascular Diseases

Chronic Administration of Mitochondrion-Targeted Peptide Ss-31 Prevents Atherosclerotic Development in Apoe Knockout Mice Fed Western Diet